CNS Drugs

, Volume 31, Issue 9, pp 737–745 | Cite as

Pharmacological Management of Bipolar Disorder in Pregnancy

Therapy in Practice

Abstract

Bipolar disorder is associated with high morbidity and mortality. The management of bipolar disorder includes a broad approach involving psychoeducation, psychological therapies and psychotropic medication. The management of bipolar disorder in pregnancy is challenging; there is an increase in the rate of relapse of bipolar disorder in the perinatal period and treatment decisions are complex as clinicians are required to weigh up the risks of untreated illness versus unwanted treatment effects on both the mother and the developing fetus. Whilst depressive relapses are more common, women are also at an increased risk of postpartum psychosis, which is a psychiatric emergency that almost always requires inpatient treatment. This paper discusses the limited evidence base regarding the safety of psychotropic medication in the perinatal period, including challenges in perinatal mental health research and the lack of robust evidence. The general principles of prescribing in pregnancy, the importance of preconception counselling, and the risks and benefits associated with antipsychotics, mood stabilisers and antidepressants are addressed.

References

  1. 1.
    Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, Suppes TM, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry. 2003;64(6):680–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–51.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Guze SB, Robins E. Suicide and primary affective disorders. Br J Psychiatry. 1970;117(539):437–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Chen YW, Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other axis I disorder. Biol Psychiatry. 1996;39(10):896–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Jones I, Craddock N. Searching for the puerperal trigger: molecular genetic studies of bipolar affective puerperal psychosis. Psychopharmacol Bull. 2007;40(2):115–28.PubMedGoogle Scholar
  6. 6.
    Jones I, Craddock N. Familiality of the puerperal trigger in bipolar disorder: results of a family study. Am J Psychiatry. 2001;158(6):913–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Heron J, Robertson Blackmore E, McGuinness M, Craddock N, Jones I. No ‘latent period’ in the onset of bipolar affective puerperal psychosis. Arch Womens Ment Health. 2007;10(2):79–81.CrossRefPubMedGoogle Scholar
  8. 8.
    Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry. 1987;150:662–73.CrossRefPubMedGoogle Scholar
  9. 9.
    Brockington IF. Puerperal psychosis, motherhood and mental health. Oxford: Oxford University Press; 1996.Google Scholar
  10. 10.
    Di Florio A, Smith S, Jones I. Postpartum psychosis. Obstet Gynaecol. 2013;15(3):145–50.Google Scholar
  11. 11.
    Di Florio A, Forty L, Gordon-Smith K, Heron J, Jones L, Craddock N, et al. Perinatal episodes across the mood disorder spectrum. JAMA Psychiatry. 2013;70:168–75.CrossRefPubMedGoogle Scholar
  12. 12.
    Munk-Olsen T, Laursen TM, Mendelson T, Pedersen CB, Mors O, Mortensen PB. Risks and predictors of readmission for a mental disorder during the postpartum period. Arch Gen Psychiatry. 2009;66:189–95.CrossRefPubMedGoogle Scholar
  13. 13.
    Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164(12):1817–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Wellings K, Jones KG, Mercer CH, Tanton C, Clifton S, Datta J, et al. The prevalence of unplanned pregnancy and associated factors in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Lancet. 2013;382(9907):1807–16.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Marengo E, Martino DJ, Igoa A, Baamonde MU, Scápola M, Fassi G, et al. Unplanned pregnancies and reproductive health among women with bipolar disorder. J Affect Disord. 2015;178:201–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Miklowitz DJ, Axelson DA, Birmaher B, George EL, Taylor DO, Schneck CD, et al. Family-focused treatment for adolescents with bipolar disorder. Results of a 2-year randomized trial. Arch Gen Psychiatry. 2008;65(9):1053–61.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Perry A, Tarrier N, Morriss R, McCarthy E, Limb K. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ. 1999;318:149–53.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Miklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry. 2003;60(9):904–12.CrossRefPubMedGoogle Scholar
  19. 19.
    Simon GE, Ludman EJ, Unützer J, Bauer MS, Operskalski B, Rutter C. Randomized trial of a population-based care program for people with bipolar disorder. Psychol Med. 2005;35(1):13–24.CrossRefPubMedGoogle Scholar
  20. 20.
    Reinares M, Colom F, Sánchez-Moreno J, Torrent C, Martínez-Arán A, Comes M, et al. Impact of caregiver group psychoeducation on the course and outcome of bipolar patients in remission: a randomised controlled trial. Bipolar Disord. 2008;10(4):511–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Colom F, Vieta E, Sánchez-Moreno J, Palomino-Otiniano R, Reinares M, Goikolea JM, et al. Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatry. 2009;194(3):260–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Spinelli MG. Maternal infanticide associated with mental illness: prevention and the promise of saved lives. Am J Psychiatry. 2004;161(9):1548–57.CrossRefPubMedGoogle Scholar
  23. 23.
    NICE. Bipolar disorder: assessment and management. Clinical guideline CG185. Sept 2014 (updated Feb 2016). https://www.nice.org.uk/guidance/cg185. Accessed 26 June 2017.
  24. 24.
    Bergink V, Bouvy PF, Vervoort JSP, Koorengevel KM, Steegers EAP, Kushner SA. Prevention of postpartum psychosis and mania in women at high risk. Am J Psychiatry. 2012;169:609–15.CrossRefPubMedGoogle Scholar
  25. 25.
    Oates M. Suicide: the leading cause of maternal death. Br J Psychiatry. 2003;183(4):279–81.CrossRefPubMedGoogle Scholar
  26. 26.
    Keck PE, McElroy SL, Strakowski SM, West SA, Sax KW, Hawkins JM, et al. 12-Month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Focus. 2003;1(1):44–52.CrossRefGoogle Scholar
  27. 27.
    Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL. The enduring psychosocial consequences of mania and depression. Am J Psychiatry. 1993;150(5):720–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Kleinman LS, Lowin A, Flood E, Gandhi G, Edgell E, Revicki DA. Costs of bipolar disorder. Pharmacoeconomics. 2003;21(9):601–22.CrossRefPubMedGoogle Scholar
  29. 29.
    Goldberg JF, Harrow M. Consistency of remission and outcome in bipolar and unipolar mood disorders: a 10-year prospective follow-up. J Affect Disord. 2004;81:123–31.CrossRefPubMedGoogle Scholar
  30. 30.
    Bodén R, Lundgren M, Brandt L, Reutfors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012;345:e7085.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich L. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry. 2005;162(1):79–91.CrossRefPubMedGoogle Scholar
  32. 32.
    Kumar R, Marks M, Platz C, Yoshida K. Clinical survey of a psychiatric and baby unit characteristics of 100 consecutive admissions. J Affect Disord. 1994;33:11–22.CrossRefGoogle Scholar
  33. 33.
    NICE. Antenatal and postnatal mental health: clinical management and service guidance. Clinical guideline CG192. Dec 2014 (updated Jun 2015). http://www.nice.org.uk/guidance/cg192. Accessed 26 June 2017.
  34. 34.
    US Food and Drug Administration. https://www.fda.gov/. Accessed 26 June 2017.
  35. 35.
    Gov.uk. Medicines & Healthcare products Regulatory Agency. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency. Accessed 26 June 2017.
  36. 36.
    Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: selective literature review. Br J Psychiatry. 2003;182(3):199–204.CrossRefPubMedGoogle Scholar
  37. 37.
    Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28:55–68.CrossRefPubMedGoogle Scholar
  38. 38.
    Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003;28(1):83–96.CrossRefPubMedGoogle Scholar
  39. 39.
    Abel KM. Fetal antipsychotic exposure in a changing landscape: seeing the future. Br J Psychiatry. 2013;202(5):321–3.CrossRefPubMedGoogle Scholar
  40. 40.
    Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2010;36(3):518–44.CrossRefPubMedGoogle Scholar
  41. 41.
    Habermann F, Fritzsche J, Fuhlbrück F, Wacker E, Allignol A, Weber-Schoendorfer C, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol. 2013;33(4):453–62.CrossRefPubMedGoogle Scholar
  42. 42.
    Boden R, Lundgren M, Brandt L, Reutfors J, Kieler H. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry. 2012;69(7):715–21.CrossRefPubMedGoogle Scholar
  43. 43.
    Lin HC, Chen IJ, Chen YH, Lee HC, Wu FJ. Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? Schizophr Res. 2010;116(1):55–60.CrossRefPubMedGoogle Scholar
  44. 44.
    McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66(4):444–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Vigod SN, Gomes T, Wilton AS, Taylor VH, Ray JG. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. BMJ. 2015;350:h2298.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Drugs.com. Clozaril. http://www.drugs.com/pro/clozaril.html. Accessed 26 July 2017.
  47. 47.
    Jansson LM, Velez M. Neonatal abstinence syndrome. Curr Opin Pediatr. 2012;24(2):252–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Elia J, Katz IR, Simpson GR. Teratogenicity of psychotherapeutic medications. Psychopharmacol Bull. 1987;23(4):531–86.PubMedGoogle Scholar
  49. 49.
    Thiels C. Pharmacotherapy of psychiatric disorder in pregnancy and during breast-feeding: a review. Pharmacopsychiatry. 1987;20:133–46.CrossRefPubMedGoogle Scholar
  50. 50.
    Warkany J. Teratogen update: lithium. Teratology. 1988;38:593–6.CrossRefPubMedGoogle Scholar
  51. 51.
    Nora J, Nora AH, Toews WH. Lithium, Ebstein’s anomaly, and other congenital heart defects. Lancet. 1974;2:594–5.CrossRefPubMedGoogle Scholar
  52. 52.
    Weinstein MR, Goldfield MD. Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry. 1975;132:529–31.CrossRefPubMedGoogle Scholar
  53. 53.
    Mcknight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379:721–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Newport DJ, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry. 2005;162(11):2162–70.CrossRefPubMedGoogle Scholar
  55. 55.
    Yacobi S, Ornoy A. Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review. Isr J Psychiatry Relat Sci. 2008;45(2):95–106.PubMedGoogle Scholar
  56. 56.
    Llewellyn A, Stowe ZN, Strader JR. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry. 1998;59(6):57–64.PubMedGoogle Scholar
  57. 57.
    Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381:1672–82.CrossRefPubMedGoogle Scholar
  58. 58.
    Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008;81(1):1–13.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Hernández-Díaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, North American AED Pregnancy Registry, North American AED Pregnancy Registry, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692–9.CrossRefPubMedGoogle Scholar
  60. 60.
    Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609–17.CrossRefPubMedGoogle Scholar
  61. 61.
    Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley R, Clayton-Smith J, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12:244–52.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Shallcross R, Bromley RL, Cheyne CP, García-Fiñana M, Irwin B, Morrow J, et al. In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. Neurology. 2014;82(3):213–21.CrossRefPubMedGoogle Scholar
  63. 63.
    Cohen MJ, Meador KJ, Browning N, May R, Baker GA, Clayton-Smith J, et al. Fetal antiepileptic drug exposure: adaptive and emotional/behavioral functioning at age 6years. Epilepsy Behav. 2013;29(2):308–15.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Bromley RL, Mawer G, Clayton-Smith J, Baker GA. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology. 2008;71(23):1923–4.CrossRefPubMedGoogle Scholar
  65. 65.
    Meador KJ, Baker GA, Browning N, Cohen MJ, Clayton-Smith J, Kalayjian LA, et al. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain. 2011;134(2):396–404.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Cunnington MC, Weil JG, Messenheimer JA, Ferber S, Yerby M, Tennis P. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology. 2011;76(21):1817–23.CrossRefPubMedGoogle Scholar
  67. 67.
    Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA. 2011;305(19):1996–2002.CrossRefPubMedGoogle Scholar
  68. 68.
    Clark C, Klein AM, Perel JM, Helsel J, Wisner KL. Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry. 2013;170(11):1240–7.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    NICE. Bipolar disorder: assessment and management. Clinical guidance CG185. http://www.nice.org.uk/guidance/cg185. Accessed 26 June 2017.
  70. 70.
    Grigoriadis S, Mamisashvili L, Ross LE. Achieving the balance: treating depressed pregnant women with antidepressants. J Clin Psychiatry. 2013;74(4):375–6.CrossRefPubMedGoogle Scholar
  71. 71.
    Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370:2397–407.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ. 2015;350:h1798.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Grigoriadis S, VonderPorten EH, Mamisashvili L, Eady A, Tomlinson G, Dennis CL, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74(4):e309–20.CrossRefPubMedGoogle Scholar
  74. 74.
    Grigoriadis S, VonderPorten EH, Mamisashvili L, Tomlinson G, Dennis CL, Koren G, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ. 2014;348:f6932.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C, et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142–51.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68(11):1104–12.CrossRefPubMedGoogle Scholar
  77. 77.
    Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ. 2013;346:f2059.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Greater Manchester Mental Health NHS Foundation TrustManchesterUK
  2. 2.National Centre for Mental Health, MRC Centre for Psychiatric Genetics and GenomicsCardiff UniversityCardiffUK

Personalised recommendations